THE DUBERSTEIN GROUP INC. for PFIZER INC.
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
India treatment of intellecutal property - Executive Branch action re this issue. Trans Pacific Partnership negotiation - Executive Branch action re this issue.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
Alcohol and Drug Abuse ALC
Opioid and prescription drug abuse.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
Taxation/Internal Revenue Code TAX
Corporate tax reform, including international taxes (deferral, excess returns/base erosion, territorial systems, patent/innovation box) - S.Con.Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023; proposed legislation re these issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
Pharmacy PHA
Pharmaceutical issues, including track and trace, and drug reimportation. Tampering with prescription pills - HR 486, Stop Tampering of Prescription Pills Act of 2013. Detromethorphan abuse - S 644, PACT Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
Health Issues HCR
Aging issues generally. Healthcare and Medicare-related amendments - S.Con.Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023.Joint research projects between NIH and pharmaceutical industry - Congressional oversight. Restrictions on over-the-counter medications for Healthcare Savings Accounts and Flexible Savings Accounts. Implementation of the Patient Protection and Affordable Health Care Act. Antibiotic incentives. Drug shortages.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
| MARTI THOMAS | — |
Medicare/Medicaid MMM
Medicare issues, including deficit reduction package, rebates, Medicare Advantage rate-setting, Part D and dual eligible rebates, non-interference, IPAB repeal.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
| DANIEL P MEYER | — |
Budget/Appropriations BUD
Impact of fiscal deficit issues, including fiscal cliff, debt ceiling, Continuing Resolution, sequestration, on healthcare - HR 8, American Taxpayer Relief Act of 2012 (112th Congress); HR 325, To ensure the complete and timely payment of the obligations of the United States Government until May 19, 2013, and for other purposes; HR 933, Consolidated and Further Continuing Appropriations Act, 2013; proposed legislation; Executive Branch action re these issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
| MARTI THOMAS | — |
Consumer Issues/Safety/Products CSP
Supply chain issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.